Financials Jul 08, 2021 07:41 PM (GMT+8)
In response to the letter of concern from AMEC, hoons global made the decision to spin off hoons bio based on its own business development, which is an important layout of its development strategy and is not set up for this transaction. Hoons global will separate the original botulinum toxin business unit and set up a subsidiary, hoons bio, to develop independently, which will not have a significant impact on hoons global. Hoons global has solvency and has issued relevant commitments to ensure that there will be no joint and several liability of hoons bio for its 42.6 billion won debt, and the possibility of joint and several liability of hoons bio is relatively small. AMEC will not have a significant adverse impact on the company's production and operation after acquiring the equity of huons bio through acquisition and capital increase.
This text is a result of machine translation.